Financials data is unavailable for this security.
View more
Year on year Zhejiang Shouxiangu Pharmaceutical Co Ltd 's revenues fell -5.39% from 829.07m to 784.35m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from 277.78m to 254.48m, a -8.39% decrease.
Gross margin | 81.12% |
---|---|
Net profit margin | 34.64% |
Operating margin | 34.89% |
Return on assets | 8.65% |
---|---|
Return on equity | 12.57% |
Return on investment | 10.50% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at Zhejiang Shouxiangu Pharmaceutical Co Ltd fell by 693.64m. However, the company earned 315.06m from its operations for a Cash Flow Margin of 40.17%. In addition the company generated 290.08m cash from financing while 1.30bn was spent on investing.
Cash flow per share | -- |
---|---|
Price/Cash flow per share | -- |
Book value per share | 10.94 |
---|---|
Tangible book value per share | 10.50 |
More ▼
Balance sheet in CNYView more
Current ratio | 3.70 |
---|---|
Quick ratio | 3.25 |
Total debt/total equity | 0.2864 |
---|---|
Total debt/total capital | 0.2226 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth dropped -11.36% and -8.82%, respectively. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
Div yield(5 year avg) | 1.01% |
---|---|
Div growth rate (5 year) | 17.13% |
Payout ratio (TTM) | 29.16% |
EPS growth(5 years) | 17.02 |
---|---|
EPS (TTM) vs TTM 1 year ago | -7.36 |
More ▼